EXELIXIS-XL092-002
Phase I
OPEN TO ACCRUAL
A Dose-Escalation and Expansion Study of the Safety and Efficacy of XL092 in Combination with Immuno-Oncology or Other Agents in Subjects with Unresectable Advanced or Metastatic Solid Tumors
HCRN-GU23-651
Phase II
OPEN TO ACCRUAL
A Randomized Phase 2 Trial of Fianlimab and Cemiplimab Plus or Minus Ipilimumab or Ipilimumab Plus Nivolumab in First-Line Advanced Renal Cell Carcinoma (RCC)
NRG-GU012-SAMURAI
Phase II
OPEN TO ACCRUAL
Randomized Phase II Stereotactic Ablative Radiation Therapy (SABR) for Metastatic Unresected Renal Cell Carcinoma (RCC) Receiving Immunotherapy (SAMURAI)